11551 related articles for article (PubMed ID: 10649252)
1. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
2. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
3. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
4. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma.
Murali R; Hughes MT; Fitzgerald P; Thompson JF; Scolyer RA
Ann Surg; 2009 Apr; 249(4):641-7. PubMed ID: 19300224
[TBL] [Abstract][Full Text] [Related]
5. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
Crocetti E; Mangone L; Lo Scocco G; Carli P
Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
[TBL] [Abstract][Full Text] [Related]
6. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
7. A population-based validation of the American Joint Committee on Cancer melanoma staging system.
Gimotty PA; Botbyl J; Soong SJ; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8065-75. PubMed ID: 16258105
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.
Leiter U; Buettner PG; Eigentler TK; Garbe C
J Clin Oncol; 2004 Sep; 22(18):3660-7. PubMed ID: 15302905
[TBL] [Abstract][Full Text] [Related]
9. Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma.
Busam KJ
Am J Clin Pathol; 2001 May; 115(5):743-6. PubMed ID: 11345839
[TBL] [Abstract][Full Text] [Related]
10. Independent prognostic importance of vascular invasion in nodular melanomas.
Straume O; Akslen LA
Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942
[TBL] [Abstract][Full Text] [Related]
11. Contemporary surgical treatment of advanced-stage melanoma.
Essner R; Lee JH; Wanek LA; Itakura H; Morton DL
Arch Surg; 2004 Sep; 139(9):961-6; discussion 966-7. PubMed ID: 15381613
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
[TBL] [Abstract][Full Text] [Related]
13. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
Nahabedian MY; Tufaro AP; Manson PN
Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
[TBL] [Abstract][Full Text] [Related]
15. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
16. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.
Francken AB; Shaw HM; Thompson JF; Soong SJ; Accortt NA; Azzola MF; Scolyer RA; Milton GW; McCarthy WH; Colman MH; McGovern VJ
Ann Surg Oncol; 2004 Apr; 11(4):426-33. PubMed ID: 15070604
[TBL] [Abstract][Full Text] [Related]
17. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.
Lindholm C; Andersson R; Dufmats M; Hansson J; Ingvar C; Möller T; Sjödin H; Stierner U; Wagenius G;
Cancer; 2004 Nov; 101(9):2067-78. PubMed ID: 15372475
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
19. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.
Gimotty PA; Elder DE; Fraker DL; Botbyl J; Sellers K; Elenitsas R; Ming ME; Schuchter L; Spitz FR; Czerniecki BJ; Guerry D
J Clin Oncol; 2007 Mar; 25(9):1129-34. PubMed ID: 17369575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
